Randomised trial of the effect of long-chain n-3 polyunsaturated fatty acids on arrhythmia recurrence in atrial fibrillation

Montreal Heart Institute (Institut de cardiologie de Montréal) (Canada)0 个研究点目标入组 332 人开始时间: 2008年6月30日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Aged greater than or equal to 18 years, either sex
•2. Written informed consent
•3. Non-valvular paroxysmal or persistent AF in whom a rhythm control strategy is planned
•4. Duration of at least one symptomatic AF episode greater than 10 minutes within the past 6 months
•5. Electrocardiogram (ECG) documentation of AF
•6. Left ventricular (LV) ejection fraction greater than 40%
•7. Normal thyroid stimulating hormone (TSH)

•1. Chronic AF (continuously present for greater than 3 months)
•2. Myocardial infarction within the past month prior to selection visit
•3. Cardiac or thoracic surgery within the past 3 months or likely to be performed during trial
•4. Moderate to severe congestive heart failure (New York Heart Association Functional Class [NHYA FC] III - IV)
•5. Left ventricular dysfunction (ejection fraction [EF] less than 40%)
•6. Mitral stenosis
•7. Moderate to severe mitral insufficiency (Grade 3 - 4/4)
•8. AF secondary to an acute reversible condition (untreated or uncontrolled hyperthyroidism, post-operative AF, fever, anaemia)
•9. Need for anti-arrhythmic therapy for a condition other than atrial fibrillation
•10. Wolff-Parkinson-White syndrome
•11. Any medical condition making compliance with study treatment unlikely
•12. Current use of n-3 fatty acid supplements or use within the past 3 months

发起方

Montreal Heart Institute (Institut de cardiologie de Montréal) (Canada)